

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Asthma	T cell immunoglobulin and mucin domain 1 (HAVCR1; TIM-1); IL-4 (BSF1); IL-13	<p>Mouse studies suggest that TIM-1 inhibition could help treat allergic asthma. In a humanized mouse model of allergic asthma, airway challenge with allergen increased immune cell infiltration and levels of human TIM-1 and IL-4 in the lungs compared with those in unchallenged controls. In challenged mice, treatment with antibody to TIM-1 decreased allergen-induced immune cell infiltration and IL-4 production to levels comparable to those seen upon treatment with an antibody to IL-13. Ongoing work by Biogen Idec Inc. includes testing the TIM-1 antibody in preclinical models of undisclosed indications. At least six companies have antibodies or compounds targeting IL-13 in Phase II testing to treat asthma.</p> <p>SciBX 3(28); doi:10.1038/scibx.2010.868 Published online July 22, 2010</p>	Patented by Biogen Idec; available for licensing	<p>Sonar, S.S. <i>et al.</i> <i>J. Clin. Invest.</i>; published online July 12, 2010; doi:10.1172/JCI39543</p> <p>Contact: Paul D. Rennert, Biogen Idec Inc., Cambridge, Mass. e-mail: paul.rennert@biogenidec.com</p>